The first large phase III trial of ipilimumab (a CTLA-4 inhibitor) plus nivolumab (a PD-1 inhibitor) in recurrent World Health Organization (WHO) grade IV glioma (glioblastoma) (NCT02017717) was initiated in 2014. The gene discussed is CTLA4; the disease is central nervous system cancer.